Success Metrics

Clinical Success Rate
76.0%

Based on 152 completed trials

Completion Rate
76%(152/200)
Active Trials
331(54%)
Results Posted
70%(106 trials)
Terminated
48(8%)

Phase Distribution

Ph phase_1
172
28%
Ph phase_4
5
1%
Ph phase_2
240
39%
Ph early_phase_1
39
6%
Ph phase_3
54
9%
Ph not_applicable
79
13%

Phase Distribution

211

Early Stage

240

Mid Stage

59

Late Stage

Phase Distribution589 total trials
Early Phase 1First-in-human
39(6.6%)
Phase 1Safety & dosage
172(29.2%)
Phase 2Efficacy & side effects
240(40.7%)
Phase 3Large-scale testing
54(9.2%)
Phase 4Post-market surveillance
5(0.8%)
N/ANon-phased studies
79(13.4%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

64.7%

152 of 235 finished

Non-Completion Rate

35.3%

83 ended early

Currently Active

331

trials recruiting

Total Trials

617

all time

Status Distribution
Active(354)
Completed(152)
Terminated(83)
Other(28)

Detailed Status

Recruiting220
Completed152
Active, not recruiting111
Terminated48
Withdrawn35
Not yet recruiting21

Development Timeline

Analytics

Development Status

Total Trials
617
Active
331
Success Rate
76.0%
Most Advanced
Phase 4

Trials by Phase

Early Phase 139 (6.6%)
Phase 1172 (29.2%)
Phase 2240 (40.7%)
Phase 354 (9.2%)
Phase 45 (0.8%)
N/A79 (13.4%)

Trials by Status

terminated488%
active_not_recruiting11118%
withdrawn356%
enrolling_by_invitation20%
not_yet_recruiting213%
suspended122%
completed15225%
unknown163%
recruiting22036%

Recent Activity

Clinical Trials (617)

Showing 20 of 617 trialsScroll for more
NCT07061977Phase 3

Induction Pembrolizumab and Chemotherapy Followed by Pembrolizumab Before Chemoradiation and Pembrolizumab Maintenance Compared to Standard Chemoradiation With Pembrolizumab Followed by Pembrolizumab Maintenance in High-Risk Cervical Cancer

Recruiting
NCT04134260Phase 3

Testing the Addition of the Drug Apalutamide to the Usual Hormone Therapy and Radiation Therapy After Surgery for Prostate Cancer, INNOVATE Trial

Recruiting
NCT06242834Phase 2

Pembrolizumab and Tazemetostat to Overcome Immune Tolerance Following ASCT or CAR T-cell Therapy in Patients With Aggressive B-Cell Non-Hodgkin's Lymphoma

Active Not Recruiting
NCT07572123Phase 2

Evaluating the Addition of Maintenance Immunotherapy Compared to the Usual Treatment of Chemotherapy and Autologous Stem Cell Transplant Alone for High-risk Patients With Relapsed or Refractory Hodgkin Lymphoma

Not Yet Recruiting
NCT06014827Phase 2

Biologically Guided Radiation Therapy (BgRT) and Stereotactic Body Radiation Therapy (SBRT) to Tyrosine Kinase Inhibitor in Oligoprogressive Oncogenic Positive Non-Small Cell Lung Carcinoma

Recruiting
NCT04609046Phase 1

Testing the Addition of Lenalidomide and Nivolumab to the Usual Treatment for Primary CNS Lymphoma

Recruiting
NCT06500481Phase 3

Testing Proton Craniospinal Radiation Therapy Versus the Usual Radiation Therapy for Leptomeningeal Metastasis, RADIATE-LM Trial

Recruiting
NCT03801876Phase 3

Comparing Proton Therapy to Photon Radiation Therapy for Esophageal Cancer

Recruiting
NCT07061964Phase 2

Combining Immunotherapy and Radiation Therapy to Help Patients Avoid Bladder Removal After Treatment Shrinks Muscle Invasive Bladder Cancer, BRIGHT Trial

Recruiting
NCT05946213Phase 3

Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer

Recruiting
NCT05050162Phase 2

Comparing Cisplatin Every Three Weeks to Cisplatin Weekly When Combined With Radiation for Patients With Advanced Head and Neck Cancer

Suspended
NCT05675410Phase 3

A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab

Recruiting
NCT06589804Phase 3

Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment

Recruiting
NCT06784726Phase 2

Odronextamab for Relapsed and Refractory Large B-cell Lymphomas Before CAR-T

Recruiting
NCT04402788Phase 2

Testing the Addition of Radiation Therapy to the Usual Immune Therapy Treatment (Atezolizumab) for Extensive Stage Small Cell Lung Cancer, The RAPTOR Trial

Recruiting
NCT06022939Phase 3

Comparing Dara-VCD Chemotherapy Plus Stem Cell Transplant to Dara-VCD Chemotherapy Alone for People Who Have Newly Diagnosed AL Amyloidosis

Recruiting
NCT04847453Phase 1

Venetoclax, MLN9708 (Ixazomib Citrate) and Dexamethasone for the Treatment of Relapsed or Refractory Light Chain Amyloidosis

Active Not Recruiting
NCT05111574Phase 2

Using Nivolumab Alone or With Cabozantinib to Prevent Mucosal Melanoma Return After Surgery

Recruiting
NCT06319027Phase 2

Identifying Findings on Brain Scans That Could Help Make Better Predictions About Brain Cancer Progression, The GABLE Trial

Recruiting
NCT05583721Phase 2

Relationship Between Abnormal Myocardial Perfusion and Diastolic Dysfunction in Sickle Cell Disease Using PET

Recruiting

Drug Details

Intervention Type
PROCEDURE
Total Trials
617